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Significant perioperative morbidity accompanies
contemporary infrainguinal bypass surgery: An
NSQIP report
Glenn M. LaMuraglia, MD,a Mark F. Conrad, MD,a Tom Chung, MA,a Matthew Hutter, MD,b
Michael T. Watkins, MD,a and Richard P. Cambria, MD,a Boston, Mass
Objectives: A variety of clinical and anatomic factors influence the choice between infrainguinal bypass surgery (BPG) and
percutaneous endovascular procedures (PTA) to treat lower extremity vascular disease. The decision, in part, is dependant
on periprocedural morbidity. The goal of this study was to document the contemporary morbidity and mortality of
infrainguinal BPG, utilizing the previously validated National Surgical Quality Improvement Program (NSQIP)
database.
Methods: Data from the private sector NSQIP, a prospectively validated systematic-sample database, using Current
Procedural Terminology (CPT) codes for all infrainguinal BPG performed between January 1, 2005, and December
31, 2006, were analyzed. Study endpoints included 30-day death and NSQIP-defined major complications,
including graft failure, differentiated between systemic vs operative-site related complications. Potentially associated
clinical variables were assessed by univariate methods to create the multivariate models of factors associated with
study endpoints.
Results: There were 2404 infrainguinal BPG (infrapopliteal distal anastomosis 42%, prosthetic 29%) performed in the
study interval with patient variables: age 67  12, male 66%, diabetes 44%, limb salvage indications 48%. The 30-day
composite mortality/major morbidity was 19.5%. The overall mortality was 2.7% and correlated with (P value, odds ratio
[OR]): patient age (<.001, 1.056), low body weight (.007, 0.988), significant preoperative dyspnea (.03, 1.97), dialysis
(.003, 5.26), history transient ischemic attack (.03, 2.43), and bleeding disorder (.02, 2.01). Major complications
occurred in 18.7% patients, including 7.4% graft thromboses, and 9.4% wound infections. Major systemic complications
occurred in 5.9% and correlated with: age (.001, 1.03), history myocardial infarction (.02, 2.37), dialysis (<.001, 2.52),
impaired sensorium (.005, 2.93), and general (vs regional) anesthesia (.04, 1.9). Major operative site-related complica-
tions occurred in 15.1% and correlated with: history chronic obstructive pulmonary disease (.04, 1.40), limb salvage
indication (<.001, 1.71), impaired sensorium (.01, 2.26), non-independent preoperative functional status (.03, 1.37),
and operative time (<.001, 1.002). The combination of dialysis and age >80 was identified as the most powerful
high-risk composite for death (13.3-fold) and major complications (2.2-fold).
Conclusion: Infrainguinal BPG is accompanied by significant major morbidity and mortality in contemporary practice.
These results reinforce the precept that stringent indications for BPG should be maintained, when considering the
method of lower extremity revascularization. (J Vasc Surg 2009;50:299-304.)The major objective in the management of patients
with peripheral vascular disease is to maintain functional
status, avoid amputation, and reduce overall mortality from
cardiovascular disease.1 In addition to conservative mea-
sures of exercise, medical therapy, and aggressive risk fac-
tors modification, lower extremity revascularization is gen-
erally considered mandatory in patients with critical limb
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doi:10.1016/j.jvs.2009.01.043ischemia (CLI) and a matter of clinical judgment in those
with disabling claudication.2 Although there is general
agreement as to what constitutes successful lower extremity
revascularization, there are no specific evidence-based cri-
teria for choosing specific therapeutic options such as per-
cutaneous therapy (PTA) or lower-extremity bypass sur-
gery (BPG).3,4 Randomized trials are few5,6 and have not
provided definitive guidelines with respect to the mode of
revascularization.2
Multiple factors, such as anatomic extent and location
of the disease, indication for revascularization, and patient
demographic characteristics figure into the decision of
method of revascularization. In addition, operator spe-
cialty, individual expertise, clinical experience, and patient
preference also drive the choice between PTA and BPG
when considering the specific patient goals.2,7 In addition,
the anatomic durability of the planned therapeutic option
and the anticipated morbidity and mortality of the proce-
dure will influence the decision whether to proceed in
claudicants and the method of revascularization in CLI
patients.3,8,9
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ization is the associated periprocedural morbidity and mor-
tality. Documentation of the short term results after BPG is
limited to single institution retrospective reports,10,11 large
databases analyses with limited data variables,12 or prospec-
tive trials,5,13 which may not reflect the cross-section of
patients or accepted treatment in present practice. To over-
come these factors, the perioperative outcomes of lower-
extremity bypass were queried from the National Surgical
Quality Improvement Program (NSQIP) for the private
sector hospitals. The goal of this study was to delineate the
contemporary perioperative morbidity and mortality of in-
frainguinal BPG and define the high-risk patient profiles in
this patient cohort.
METHODS
Database. The private sector NSQIP is a validated,
independently adjudicated, prospective database of a sys-
tematic sample of cases which provides detailed patient
demographics and procedural data with 30-day mortality
and major and minor morbidity.14 From 2005 through
2006, the number of hospitals contributing to the database
increased from 37 to 121. Sixty-five percent and 60% were
classified as academic/teaching institutions for each of the
2 years respectively, while the remainders were labeled as
community hospitals. During the study, the average hospi-
tal sizes relative to patient beds were: 56% (500), 27%
(300-499), 14% (100-299), and 3% (100).
The database was queried to provide detailed patient
clinical and demographic data, periprocedural information,
and 30-day specific outcome of mortality and morbidity as
previously described. Approval was obtained from the In-
stitutional Review Board of the Human Studies Commit-
tee.
Selected sample. Patients were queried using the Cur-
rent Procedural Terminology (CPT) for all infrainguinal
bypass procedures that were done between January 1,
2005, and December 31, 2006, for procurement of the
data. This comprised anonymous records from all partici-
pating private sector academic and nonacademic hospitals
that were contributing to the program. Patient data was
obtained per procedural code and included 30-day out-
come. However, correlation of the specific index BPG
procedure to any prior or subsequent operations or inter-
vention on the same patient in the 30-day period was not
possible.
Patient demographic clinical characteristics. Patient de-
mographic and clinical co-morbid conditions, available
from the NSQIP database,15 were obtained for each of the
patients and were cataloged as previously described.16 In
addition, based on the CPT code and the NSQIP database
data, the surgical details for each of the lower extremity
bypass procedures were retrieved and used for outcome
analysis. Laboratory data other than creatinine was not
available for all patients and, therefore, not included in the
data analysis.
Outcomes. The 30-day mortality and major morbid-
ity were the primary endpoints of the study. The individualmajor complications is a slight modification of the criteria
that has been previously defined16 to also include bypass
graft failure. The incidence of death and major complica-
tions was counted per patient who had one or more of these
events occur, while the occurrence of the major complica-
tions were counted by the incidence of each event occur-
rence. To better identify the effect that the patient and
procedural parameters may have on the outcomes, the
complications were also divided and separately analyzed
into those resulting in operative site-related or systemic
events.
Statistical analysis. Baseline characteristics were com-
pared across groups using 2 and Fisher’s exact t test where
appropriate. Multivariate analysis was performed using for-
ward stepwise logistic regression and included univariate
associations with a P  .05 of non-confounding variables.
For outcomes with low event rates, multivariate modeling
was limited to 10% of the number of events to control for
overfitting. To identify a high-risk composite of patient
variables, relative risk scores were computed from the most
significant multivariate predictors of adverse events that
had an incidence of at least 5% in the patient population. All
statistical analyses were performed using SPSS version 15.0
(SPSS Inc, Chicago, Ill).
RESULTS
During the study period, there were 2404 patients
identified in the database who underwent an infrainguinal
BPG and their demographic and clinical features are de-
tailed in Table I. Prior coronary revascularization was noted
in 45.8% of patients. There were 44.4% diabetics, approxi-
mately half of which were on insulin therapy. Of the 23.4%
of patients whose baseline creatinine was over 1.5 mg/dL,
7.9%were on dialysis. The indication for surgery was CLI in
47.6% of patients with 37% having a non-healing wound. A
vein conduit was used in 67.7% of patients and the infrap-
opliteal arteries were used for the distal anastomosis in
42.4% of cases. Detailed demographic, clinical, and proce-
dural data is summarized in Tables I and II.
There were 65 patient deaths that occurred within 30
days for an incidence of 2.7%, a major complication rate of
18.7% for a composite major morbidity and mortality of
19.7% (Table III). There was a very significant and direct
correlation of mortality and major systemic complications
with increasing age (Table IV, online only), indeed there
was a 10-fold increase in mortality and 3.5-fold increase in
major systemic complications between the lowest and high-
est quartile of patient age. This age correlation did not hold
true for all major complications nor with major operative
site complications which had a threefold higher incidence
than major systemic complications (Table V, online only).
As expected, there was a higher incidence of death
(3.6% vs 2.0%, P  .023) and major complications (30.1%
vs 16.3%, P  .0001) in patients who underwent lower
extremity bypass for CLI. However, this difference was
greater for the major operative site complications (23.9% vs
12.8%) as compared to the major systemic complications
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patients.
Univariate analysis was computed for each of the de-
Table I. Demographics and clinical features
Demographics All patients N  2404
Age (excl. ‘90’ patients) 67.0  11.8 [17-89] {68}
Gender – Male 65.9% (1585/2404)
Race – White 70.3% (1691/2404)
Race – Black 14.0% (336/2404)
BMI (kg/m2) 27.7  6.4 [10.7-92.9] {26.9}
Respiratory
Smoking (within 1 year) 39.9% (959/2404)
Severe COPD 12.0% (289/2404)
Cardiovascular
Hx CHF (within 1 month) 3.4% (82/2404)
Hx MI (within 6 months) 2.7% (66/2404)
Prior PCI 19.5% (468/2404)
Prior CS 26.3% (633/2404)
Critical limb ischemia 47.6% (1144/2404)
Diabetes
Insulin 24.1% (580/2404)
Oral agent 20.3% (488/2404)
Dialysis 7.9% (189/2404)
Preop creatinine 1.5 mg/dL 23.4% (563/2404)
Neurological
Impaired sensorium 2.1% (50/2404)
History TIA 6.4% (154/2404)
Other
Open wound 37.0% (890/2404)
Weight loss 1.7% (41/2404)
Bleeding disorder 21.5% (518/2404)
Independent functional status 80.9% (1944/2404)
BMI, Body Mass Index; CHF, congestive heart failure; COPD, chronic
obstructive pulmonary disease; CS, cardiac surgery; Hx, history; MI, myo-
cardial infarction; PCI, percutaneous cardiac intervention; TIA, transient
ischemic attack.
Table II. Procedural detail
Interventional detail All patients
Prior operation (within 30
days) 8.6% (101/1178)
Total anesthesia time
(minutes) 311.5  116.9 [54-888] {289}
Operative time (minutes) 237.1  104.6 [11-790] {218}
Anesthesia
General 85.2% (2049/2404)
Spinal 7.6% (183/2404)
Epidural 7.2% (172/2404)
Inflow
Femoral 86.6% (2082/2404)
Popliteal 10.3% (248/2404)
Other (popliteal aneurysm) 3.1% (74/2404)
Outflow
Popliteal 54.5% (1311/2404)
Distal 42.4% (1019/2404)
Other (popliteal aneurysm) 3.1% (74/2404)
Graft
Vein 55.2% (1328/2404)
Vein in situ 12.5% (301/2404)
Non-vein 29.2% (701/2404)
Other (popliteal aneurysm) 3.1% (74/2404)mographics and patient co-morbidities for the outcome ofmortality and the major complications and its subsets
(Tables V-VIII, online only). Diabetes and a recent history
of myocardial infarction (MI) within the last 6 months
surprisingly did not correlate with perioperative death,
while any dyspnea, history of congestive heart failure, and
renal insufficiency were strong markers for perioperative
mortality. Of note, diabetes was not a predictor of major
operative site or systemic complications, while impaired
renal function or dialysis was not a significant predictor of
major operative site complications.
From these univariate methods, multivariate logistic
regression models were constructed to identify patient pre-
dictors for mortality (Table IX) and morbidity (Tables
X-XII). With the creation of high-risk composites from
these significant correlate variables for death and major
complications, the composite that carried the highest pre-
dictive value was that of dialysis and age 80 years, which
carried a 13.3-fold increase risk for mortality and a 2.2-fold
increase in major complications.
DISCUSSION
The initial Congressional mandate for the NSQIP pro-
gram to provide the Veterans’ Administration (VA) system
Table III. Incidence of major postoperative occurrences
Postoperative occurrences All patients
Death 2.7% (65/2404)
Major complications 18.7% (450/2404)
Major complications – Operative site 15.1% (364/2404)
Wound dehiscence 1.7% (40/2404)
Wound infection 3.3% (80/2404)
Organ space infection 0.5% (11/2404)
Sepsis 3.9% (93/2404)
Bleed 1.6% (39/2404)
Graft failure 7.4% (178/2404)
Major complications – Systemic 5.9% (141/2404)
Failure to wean 48 hours 1.7% (41/2404)
Unplanned re-intubation 2.3% (55/2404)
Pneumonia 2.1% (50/2404)
Acute renal failure 0.5% (11/2404)
Pulmonary embolism 0.0% (1/2404)
Stroke 0.5% (12/2404)
Coma 24 hours 0
Cardiac arrest 1.0% (23/2404)
Deep venous thrombosis 1.1% (26/2404)
Table IX. Multivariate analysis on death
Variable OR [95% CI] P value
Age 1.056 [1.02-1.09] .0001
Weight 1.011 [1.00-1.02] .012
Any dyspnea 1.887 [1.08-3.58] .038
Dialysis 8.40 [1.79-15.4] .0001
Hx TIA 2.29 [1.10-5.38] .041
Bleeding disorder 1.969 [1.12-3.61] .023
TIA, Transient ischemic attack.
Age, Weight – Continuous variables.with a prospective, accurate benchmark of the perioperative
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with success in reducing complications and fostered other
quality of care initiatives.17 Thus, this database provides a
benchmark to document validated 30-day outcomes of con-
temporary infrainguinal BPG in an era with exponential rise of
PTA procedures to treat infrainguinal disease.18-20 In addi-
tion, there is limited comprehensive data on this topic with
retrospective single center studies10,11 and recently published
prospective multicenter studies, the Project of Ex-Vivo vein
graft Engineering via Transfection III (PREVENT III),13
the Bypass vs Angioplasty in Severe Ischemia of the Leg
(BASIL),5 and theDutch trial.6However, their drawback is
the restrictive inclusion criteria for the patients to enter
such a study resulting in a select cohort of patients that do
not reflect the general population of patients in everyday
practice undergoing infrainguinal BPG. Indeed, the BASIL
randomized trial, designed to compare infrainguinal BPG
Table X. Multivariate analysis of all major complications
Variable OR [95% CI] P value
Critical limb ischemia 1.62 [1.30-2.03] .001
Creatinine 1.07 [1.003-1.13] .040
Impaired sensorium 2.59 [1.43-4.69] .002
Operative time 1.002 [1.00-1.003] .001
Infrapopliteal anastomosis 1.30 [1.03-1.64] .029
Functional status:
Non-independent 1.77 [1.37-2.29] .001
OR, Odds ratio; CI, confidence interval.
Creatinine, Operative time – Continuous variables.
Table XI. Multivariate analysis of operative-site major
complications
Variable OR [95% CI] P value
Severe COPD 1.405 [1.01-1.95] 0.043
Impaired sensorium 2.26 [1.21-4.24] 0.011
Functional status:
Non-independent 1.372 [1.04-1.82] 0.027
Operative time 1.002 [1.00-1.003] 0.001
Critical limb ischemia 1.712 [1.35-2.17] 0.001
COPD, Chronic obstructive pulmonary disease; OR, odds ratio; CI, confi-
dence interval.
Operative Time – Continuous variable.
Table XII. Multivariate analysis for systemic major
complications
Variable Odds ratio P value
Age 1.033 [1.02-1.05] 0.0001
Hx MI 2.37 [1.14-4.90] 0.020
Dialysis 2.52 [1.56-4.07] 0.0001
Impaired sensorium 2.93 [1.37-6.25] 0.005
General anesthesia 1.901 [1.03-3.52] 0.040
MI, Myocardial infarction; Hx, history.
Age  Continuous variable.vs PTA for first-“intention to treat” for CLI, identified ahigher mortality (5.6% vs 2.7%), and cardiopulmonary
complications (14.2% vs 3.1%) compared to the present
study. However, this can be explained by the populations
studied: BASIL trial vs this NSQIP study having only CLI
(100% vs 46%) and an older population 70 years of age
(65% vs 46%), both variables identified in this series to
correlate with mortality and morbidity.
Lower extremity bypass is a very effective and durable
method to revascularize the ischemic leg.10,11 Prior publi-
cations focused on BPG patency, limb salvage rates, and
amputation-free survival10,21,22 rather than perioperative
complications since, until recently, there was little evidence
of effective alternative procedures. In essence, the periop-
erative morbidity and mortality was regarded as the ac-
knowledged risk for the patients to obtain the necessary
lower extremity revascularization. With the recognition of
PTA as an alternative for lower extremity reconstruction in
selected circumstances,3,19,20 the perioperative outcomes
of lower extremity BPG become more relevant in making
the proper recommendations for lower extremity revascu-
larization in an individual patient. This is especially true in
lower extremity revascularization compared to other open
vascular surgery procedures because of the acknowledged
more limited longevity and high incidence of systemic
cardiovascular co-morbidities in this patient popula-
tion.23,24 Thus, the data detailed in this study, by virtue
of its broad inclusion criteria and multiple centers, repre-
sents the “real world” expectation of contemporary mor-
bidity and mortality of infrainguinal BPG.
The 30-day mortality in this study was 2.7% and com-
pared somewhat favorably to earlier studies of infrainguinal
BPG: 3.7%,10 and was equivalent to more contemporary
reports: 2.6%,11 2.7%,25 and 1.6%.26 Though the patient
populations may not be totally comparable, this contrasts
infrainguinal PTA periprocedural mortality reported from
0%3 to 0.5%4 in most studies and 3% in the BASIL trial.5
The two most powerful clinical variables that correlated
with death in this study were dialysis and advanced patient
age, which when combined as a high-risk composite, dial-
ysis and patients over 80 years of age resulted in a significant
increase risk of death (13.3-fold) and major complications
(2.2-fold). With the reported 5-year survival of a dialysis
patient undergoing infrainguinal BPG is only 5%,27 and
with the dismal perioperative outcome for elderly dialysis
patients identified in this study, it would follow that an
infrainguinal BPG should rarely be considered in such a
patient and only after all other options have been ex-
hausted. The other alternative treatments that should be
considered in this patient population include PTA,28 pri-
mary amputation,29 and wound care management.30
With the emergence of PTA as a less invasive alternative
to BPG,9,19 a focus in patient functional and postoperative
recovery state after infrainguinal BPG has emerged.31 Al-
though the goal of limb salvage remains paramount in
determining functional outcome, several reports under-
lined the significant morbidity and importance of the func-
tional outcome and recovery after infrainguinal BPG.31,32In the present study, the incidence of major complications
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site complications compared to systemic complications,
most of which would be expected to delay recovery. Essen-
tially half of the operative site problems related to acute
30-day graft failure which was identified at 7.4%, while the
remainder of these complications was related to bleeding
and wound infections/dehiscence.
This rate of acute graft occlusion is somewhat higher
in the present study when compared to other large,
retrospective, single center reports including: 4.0%10
and 5.2%.13 There may be several reasons for this difference
which include a higher capture with prospective data col-
lection and multicenter outcomes and no available data of
the surgeons’ individual qualifications, training, or exper-
tise. In this presented report, the only common correlate
with a VA study which identified a 4.9% graft failure rate33
was infrapopliteal distal anastomosis, but not age, or race,
despite similar percentages of African American race (14%
vs 17%). Another study34 reported a fourfold higher signif-
icant incidence of acute infrainguinal BPG thrombosis with
the use of general as compared to regional anesthesia.
General anesthesia was not identified as an individual cor-
relate with operative site complications which includes graft
thrombosis in this study despite the over 85% utilization of
general anesthesia in the present study. Other than graft
failure and bleeding, local wound problems and infections
comprised 8.8% of complications. This is the most difficult
and subjective morbidity to quantify as reflected by the
wide range of reported wound infections as: 11.4%35 and
39%5 likely with different definitions and inclusion criteria.
However, the results are similar when comparing the
present study results with a VA NSQIP report of 18,217
patients undergoing infrainguinal bypass with a wound
infection rate of 12%.36 There was also agreement that renal
dysfunction did not significantly correlate to wound infec-
tion or graft failure, but did significantly correlate to death.
An interesting finding was the few major cardiac com-
plications (1.0%) in this study compared to others (3.9-
7.9%) recently reported in the literature.5,13,35 This result
may be underestimated, since routine EKG and cardiac
enzymes were not routinely checked. In addition, over 45%
of patients in this study had a prior coronary revasculariza-
tion before their lower extremity bypass.37 Despite this, the
history of having anMI within the last year was identified as
a significant variable for the development of a systemic
major complication, but not necessarily of a cardiac nature.
There are clearly multiple factors including: procedural
indications, patient clinical variables, availability of conduit,
and expected patient longevity that come into play to guide
the recommendations for lower extremity revasculariza-
tion. Appreciating this significant current mortality and
morbidity with infrainguinal BPG even with contemporary
improvements in healthcare,38 the results reported herein
require a perspective with available alternatives. A consen-
sus is emerging that PTA is a viable and effective initial
therapy, when anatomically feasible, if one accepts an ap-
proximately 15-20% reintervention rate to achieve patency
and a 5% surgical bailout rate.3,4 This study reinforces suchan approach owing to the significant morbidity and mor-
tality of BPG and identifies patient subgroups at particu-
larly high risk for whom every effort should be provided for
an alternative therapeutic approach: percutaneous angio-
plasty alone,3,4,7 hybrid surgical and catheter-based proce-
dures,39 or supportive care that may ultimately result in a
primary amputation.29 Though infrainguinal BPG provides
excellent durability to infrainguinal BPG, stringent indica-
tions should be maintained due to the significant associated
perioperative morbidity.
Shortcomings. A shortcoming of this study is that the
patient database is based on CPT codes, and as such it is not
known if these were primary or reoperative procedures. In
addition, due to maintaining the confidentiality of the
patients, the index case has no specific linked follow-up
management information during or following the 30-day
time period. In this NSQIP study, therefore, there can be
no correlation of a complication, such as graft failure, with
a specific procedure or clinical outcome, such as limb
salvage. There are also no clinical guidelines for the treat-
ment choices of these patients, or the qualifications of the
surgeons performing the operations. As such, it is unknown
how many patients were offered other treatment options,
or treated conservatively without a bypass procedure.
Though these factors are shortcomings to identify the
ultimate patient outcome, these data still provide a very
robust and complete reflection of the incidence of 30-day
mortality and morbidity in contemporary practice for in-
frainguinal bypass.
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Volume 50, Number 2 LaMuraglia et al 304.e1Table IV, online only. Perioperative death and major com
Age: Less than 60 y
Perioperative death 0.6% (4/618) 2
Major complications – ALL 19.1% (118/618) 17
Major complications – operative site 17.5% (108/618) 13
Major complications – systemic 2.6% (16/618) 5
Table V, online only. Univariate analysis of death
Demographics
Death rate for
without como
(Mean 
denote survi
Age (excl. ‘90’ patients) 66.8  11.8 [17-
Age 80 (incl. ‘90’ cases) 2.0% (41/2001)
Gender - Female 2.4% (38/1585) [
BMI (kg/m2) 27.7  6.4 [10.7
Respiratory
Smoking (within 1 year) 3.5% (49/1445)
Severe COPD 2.5% (53/2115)
Any dyspnea 2.3% (44/1924)
Cardiovascular
Hx CHF 2.5% (58/2322)
Hx MI 2.6% (61/2338)
Prior PCI 2.6% (51/1936)
Prior CS 2.5% (45/1771)
Critical limb ischemia 2.0% (25/1260)
Renal/metabolic
Diabetes – Insulin 2.6% (47/1824) [
Dialysis 1.9% (41/2215)
Preop creatinine 1.52  1.52 [0.3
Preoperative Cr 1.5 1.7% (32/1841)
Neurological
Impaired sensorium 2.5% (60/2354)
Hx TIA 2.4% (55/2250)
Other
Wound infection 2.4% (36/1514)
Weight loss 2.6% (62/2363)
Bleed disorder 2.2% (42/1866)
Functional status non-independent 1.9% (36/1944)
Interventional detail
Total anesthesia time 310.8  116.4 [54
Operative time 236.5  217.0 [11
Inflow – Femoral 2.4% (6/248) [po
Outflow – Distal 2.1% (28/1311) [
Graft material – Non-vein 2.6% (43/1629) [
Anesthesia – General vs other 2.3% (8/355)
BMI, Body Mass Index; COPD, chronic obstructive pulmonary disease; CH
intervention; CS, cardiac surgery; TIA, transient ischemic attack; SD, standplications stratified by age quartile
60-69 y 70-79 y 80 y P value
.5% (17/691) 2.9% (20/692) 6.0% (24/403) .001
.4% (120/691) 18.1% (125/692) 21.6% (87/403) .353
.7% (95/691) 13.6% (94/692) 16.6% (67/403) .129patients
rbidity
SD
vors)
Death rates for patients
with comorbidity
(Mean  SD
denote deaths) P value
89] {67} 74.3  9.0 [52-89] {76} .001
6.0% (24/403) .001
male] 3.3% (27/819) [female] .198
-82.9] 24.5  23.7 [15.7-43.0] .001
1.7% (16/959) .011
4.2% (12/289) .106
4.4% (21/480) .012
8.5% (7/82) .001
6.1% (4/66) .101
3.0% (14/468) .669
3.2% (20/633) .410
3.5% (40/1144) .022
none/oral] 3.1% (18/580) [insulin] .496
12.7% (24/189) .001
-14.1] {1.1} 2.95  2.75 [0.7-12.0] {1.5} .001
5.9% (33/563) .001
10.0% (5/50) .010
6.5% (10/154) .003
3.3% (29/890) .199
7.3% (3/41) .097
4.4% (23/518) .006
6.3% (29/460) .001
-888] 336.5  130.9 [125-714] .001
-790] 259.6  117.1 [90-617] .079
pliteal] 2.8% (58/2082) [femoral] .739
popliteal] 3.5% (36/1019) [distal] .041
vein] 3.0% (21/701) [non-vein] .630
2.8% (57/2049) .571
F, congestive heart failure; MI, myocardial infarction; PCI, percutaneous cardiac
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Demographics
Major comp. rate for patients
w/o comorbidity
Major comp. rates for patients
with comorbidity P
Age (excl. ‘90’ patients) 67.0  11.7 [17-89] 67.2  12.1 [20-89] .714
Age  80 (incl. ‘90’ cases) 18.1% (363/2001) 21.6% (87/403) .106
Gender - Female 17.5% (277/1585) 21.1% (173/819) .030
BMI (kg/m2) 27.7  6.4 [10.7-92.9] {27.0} 27.5  6.3 [11.7-62.4] {26.6} .592
Respiratory
Smoking (within 1 year) 19.0% (274/1445) 18.4% (176/959) .708
Severe COPD 18.2% (384/2115) 22.8% (66/289) .056
Any dyspnea 18.2% (351/1924) 20.6% (99/480) .231
Cardiovascular
Hx CHF 18.3% (425/2322) 30.5% (25/82) .005
Hx MI 18.3% (429/2338) 31.8% (21/66) .006
Prior PCI 18.0% (349/1936) 21.6% (101/468) .077
Prior CS 18.5% (328/1771) 19.3% (122/633) .677
Critical limb ischemia 14.1% (178/1260) 23.8% (272/1144) .001
Renal/metabolic
Diabetes – Insulin 17.8% (325/1824) 21.6% (125/580) .045
Dialysis 17.9% (397/2215) 28.0% (53/189) .001
Preoperative creatinine 16.7% (308/1841) 25.2% (142/563) .001
Preoperative Cr 1.5 1.50  1.52 [0.3-14.1] {1.1} 1.80  1.84 [0.4-11.8] {1.1} .001
Neurological
Impaired sensorium 18.1% (427/2354) 46.0% (23/50) .001
Hx TIA 18.5% (416/2250) 22.1% (34/154) .269
Other
Wound infection 17.0% (257/1514) 21.7% (193/890) .004
Weight loss 18.5% (437/2363) 31.7% (13/41) .032
Bleed disorder 18.9% (357/1886) 18.0% (93/518) .614
Functional status non-independent 16.0% (312/1944) 30.0% (138/460) .001
Interventional detail
Total anesthesia time 306.2  113.8 [54-858] 334.2  126.8 [85-888] .001
Operative time 232.4 101.7 [11-776] 257.9  114.1 [47-790] .001
Inflow – Femoral 21.0% (52/248) [popliteal] 18.8% (392/2082) [femoral] .417
Outflow – Distal 15.9% (209/1311) [popliteal] 23.1% (235/1019) [distal] .001
Graft material – Non-vein 19.0% (310/1629) [vein] 19.1% (134/701) [non-vein] .962
Anesthesia – General vs other 15.2% (54/355) [spinal/epid.] 19.3% (396/2049) [general] .066BMI, Body Mass Index; COPD, chronic obstructive pulmonary disease; Hx, history; CHF, congestive heart failure; MI, myocardial infarction; PCI,
percutaneous cardiac intervention; CS, cardiac surgery; TIA, transient ischemic attack; w/o, without.
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Demographics
Major operative site comp. rate
for patients w/o comorbidity
Major operative site comp.
rates for patients with
comorbidity P value
Age (excl. ‘90’ patients) 67.1  11.7 [17-89] 66.4  12.3 [20-88] .305
Age 80 (incl. ‘90’ cases) 14.8% (297/2001) 16.6% (67/403) .362
Gender - Female 13.9% (221/1585) 17.5% (143/819) .023
BMI (kg/m2) 27.6  6.4 [10.7-92.9] 27.8  6.4 [11.7-62.4] .724
Respiratory
Smoking (within 1 year) 14.8% (214/1445) 15.6% (150/959) .578
Severe COPD 14.6% (309/2115) 19.0% (55/289) .049
Any dyspnea 14.9% (286/1924) 16.3% (78/480) .449
Cardiovascular
Hx CHF 15.0% (348/2322) 19.5% (16/82) .261
Hx MI 15.0% (350/2338) 21.2% (14/66) .163
Prior PCI 14.6% (283/1936) 17.3% (81/468) .145
Prior CS 14.9% (263/1771) 16.0% (101/633) .505
Critical limb ischemia 11.3% (143/1260) 19.3% (221/1144) .001
Renal/metabolic
Diabetes – Insulin 14.5% (264/1824) 17.2% (100/580) .105
Dialysis 14.9% (330/2215) 18.0% (34/189) .255
Preoperative creatinine 1.54  1.57 [0.3-14.1] 1.67  1.70 [0.4-11.8] .163
Preoperative Cr 1.5 14.2% (261/1841) 18.3% (103/563) .017
Neurological
Impaired sensorium 14.7% (347/2354) 34.0% (17/50) .001
Hx TIA 14.8% (334/2250) 19.5% (30/154) .120
Other
Wound infection 13.7% (208/1514) 17.5% (156/890) .012
Weight loss 15.0% (355/2363) 22.0% (9/41) .220
Bleed disorder 15.3% (288/1886) 14.7% (76/518) .782
Functional status non-independent 13.7% (266/1944) 21.3% (98/460) .001
Interventional detail
Total anesthesia time 307.0  114.3 [54-858] 336.5 127.8 [96-888] .001
Operative time 232.9  102.1 [11-776] 261.0  114.8 [47-790] .001
Inflow – Femoral 16.1% (40/248) [popliteal] 15.3% (318/2082) [femoral] .724
Outflow – Distal 12.7% (166/1311) [popliteal] 18.8% (192/1019) [distal] .001
Graft Material – Non-vein 16.4% (115/701) 14.9% (243/1629) .361
Anesthesia – General vs other 13.5% (48/355) 15.4% (316/2049) .356BMI, Body Mass Index; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; MI, myocardial infarction; PCI, percutaneous cardiac
intervention; CS, cardiac surgery; TIA, transient ischemic attack; Hx, history; w/o, without.
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Demographics
Major systemic comp. rate
for patients w/o
comorbidity
Major systemic comp. rates
for patients with
comorbidity P value
Age (excl. ‘90’ patients) 66.7  11.8 [17-89] {67} 71.1  10.3 [36-89] {73} .001
Age 80 (incl. ‘90’ cases) 5.2% (105/2001) 8.9% (36/403) .004
Gender - Female 5.6% (88/1585) 6.5% (53/819) .363
BMI (kg/m2) 27.7  6.4 [10.7-92.9] 26.5  5.9 [16.7-52.6] .025
Respiratory
Smoking (within 1 year) 6.8% (98/1445) 4.5% (43/959) .019
Severe COPD 5.7% (120/2115) 7.3% (21/289) .280
Any dyspnea 5.7% (109/1924) 6.7% (32/480) .404
Cardiovascular
Hx CHF 5.6% (131/2322) 12.2% (10/82) .013
Hx MI 5.6% (131/2338) 15.2% (10/66) .001
Prior PCI 5.6% (109/1936) 6.8% (32/468) .318
Prior PCS 5.7% (101/1771) 6.3% (40/633) .571
Critical limb ischemia 4.8% (61/1260) 7.0% (80/1144) .025
Renal/metabolic
Diabetes – Insulin 5.6% (103/1824) 6.6% (38/580) .419
Dialysis 5.2% (115/2215) 13.8% (26/189) .001
Preoperative creatinine 1.52  1.55 [0.3-14.1] 2.11  1.96 [0.5-11.5] .001
Preoperative Cr 1.5 4.5% (83/1841) 10.3% (58/563) .001
Neurological
Impaired sensorium 5.6% (131/2354) 20.0% (10/50) .001
Hx TIA 5.8% (130/2250) 7.1% (11/154) .486
Other
Wound infection 5.5% (84/1514) 6.4% (57/890) .388
Weight loss 5.8% (137/2363) 9.8% (4/41) .299
Bleed disorder 5.9% (111/1886) 5.8% (30/518) .936
Functional status non-independent 4.2% (82/1944) 8.7% (59/460) .001
Interventional detail
Total anesthesia time 310.0  115.3 [54-858] 333.9  138.0 [85-888] .019
Operative time 236.1  103.1 [11-776] 254.6  124.8 [47-790] .041
Inflow – Femoral 6.5% (16/248) 6.0% (124/2082) .756
Outflow – Distal 5.2% (68/1311) 7.1% (72/1019) .058
Graft material – Non-vein 5.9% (96/1629) 6.3% (44/701) .721
Anesthesia – General vs other 3.4% (12/355) 6.3% (129/2049) .031BMI, Body Mass Index; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; MI, myocardial infarction; PCI, percutaneous cardiac
intervention; CS, cardiac surgery; TIA, transient ischemic attack; Hx, history; w/o, without.
